BACKGROUND: Acute and chronic exposure to cannabinoids has been associated with cognitive deficits, a higher risk for schizophrenia and other drug abuse. However, the precise mechanism underlying such effects is not known. Preclinical studies suggest that cannabinoids modulate brain-derived neurotrophic factor (BDNF). Accordingly, we hypothesized that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the principal active component of cannabis, would alter BDNF levels in humans. MATERIALS AND METHODS:Healthy control subjects (n = 14) and light users of cannabis (n = 9) receivedintravenous administration of (0.0286 mg/kg) Delta(9)-THC in a double-blind, fixed order, placebo-controlled, laboratory study. Serum sampled at baseline, after placebo administration, and after Delta(9)-THC administration was assayed for BDNF using ELISA. RESULTS:Delta(9)-THC increased serum BDNF levels in healthy controls but not light users of cannabis. Further, light users of cannabis had lower basal BDNF levels. Delta(9)-THC produced psychotomimetic effects, perceptual alterations, and "high" and spatial memory impairments. IMPLICATIONS: The effects of socially relevant doses of cannabinoids on BDNF suggest a possible mechanism underlying the consequences of exposure to cannabis. This may be of particular importance for the developing brain and also in disorders believed to involve altered neurodevelopment such as schizophrenia. Larger studies to investigate the effects of cannabinoids on BDNF and other neurotrophins are warranted.
RCT Entities:
BACKGROUND: Acute and chronic exposure to cannabinoids has been associated with cognitive deficits, a higher risk for schizophrenia and other drug abuse. However, the precise mechanism underlying such effects is not known. Preclinical studies suggest that cannabinoids modulate brain-derived neurotrophic factor (BDNF). Accordingly, we hypothesized that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the principal active component of cannabis, would alter BDNF levels in humans. MATERIALS AND METHODS: Healthy control subjects (n = 14) and light users of cannabis (n = 9) received intravenous administration of (0.0286 mg/kg) Delta(9)-THC in a double-blind, fixed order, placebo-controlled, laboratory study. Serum sampled at baseline, after placebo administration, and after Delta(9)-THC administration was assayed for BDNF using ELISA. RESULTS:Delta(9)-THC increased serum BDNF levels in healthy controls but not light users of cannabis. Further, light users of cannabis had lower basal BDNF levels. Delta(9)-THC produced psychotomimetic effects, perceptual alterations, and "high" and spatial memory impairments. IMPLICATIONS: The effects of socially relevant doses of cannabinoids on BDNF suggest a possible mechanism underlying the consequences of exposure to cannabis. This may be of particular importance for the developing brain and also in disorders believed to involve altered neurodevelopment such as schizophrenia. Larger studies to investigate the effects of cannabinoids on BDNF and other neurotrophins are warranted.
Authors: Nadia Solowij; Robert S Stephens; Roger A Roffman; Thomas Babor; Ronald Kadden; Michael Miller; Kenneth Christiansen; Bonnie McRee; Janice Vendetti Journal: JAMA Date: 2002-03-06 Impact factor: 56.272
Authors: Jose Luis López-Sendón Moreno; Juan García Caldentey; Patricia Trigo Cubillo; Carolina Ruiz Romero; Guillermo García Ribas; M A Alonso Alonso Arias; María Jesús García de Yébenes; Rosa María Tolón; Ismael Galve-Roperh; Onintza Sagredo; Sara Valdeolivas; Eva Resel; Silvia Ortega-Gutierrez; María Laura García-Bermejo; Javier Fernández Ruiz; Manuel Guzmán; Justo García de Yébenes Prous Journal: J Neurol Date: 2016-05-09 Impact factor: 4.849
Authors: Tim McQueeny; Claudia B Padula; Jenessa Price; Krista Lisdahl Medina; Patrick Logan; Susan F Tapert Journal: Behav Brain Res Date: 2011-06-02 Impact factor: 3.332